Phase II
Adaptimmune said that afamitresgene autoleucel (afami-cel) had a significantly positive effect on patients diagnosed with myxoid/round cell liposarcoma (MRCLS) and advanced synovial sarcoma.
As the capabilities have been proven, AI is establishing a firm foothold in the key areas of R&D, drug development, clinical trials, and, to some extent, patient-facing products.
Eisai and Biogen announced positive updates on the Phase IIB 201 and open-label extension studies they are conducting on the use of lecanemab to treat early Alzheimer’s Disease.
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
The drug for treatment-resistant depression reportedly demonstrated significant improvement in patients at its highest dose of 25 mg. Here’s more about it.
Sungho Han, Ph.D., founder and CEO of Genuv Inc. in Seoul, South Korea, has built her career and her company by thinking outside the box.
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Pfizer plans to seek Emergency Use Authorization for an antiviral COVID-19 treatment following an interim analysis of Phase II/III data that show statistically and clinically meaningful results.
Sangamo Therapeutics announced positive preliminary findings from its ongoing Phase I/II STAAR clinical trial in Fabry disease.
PRESS RELEASES